|
Published by: Espicom Healthcare Intelligence
Published: Mar. 6, 2008 - 74 Pages
Table of Contents
- FOREWORD
- EXECUTIVE SUMMARY
- BACKGROUND TO THE MARKET
- Geography
- Map of Australia
- Political Overview
- Economic Overview
- Estimated/Projected GDP, 2007-2012
- Demographics
- Population
- Population, June 1995-2006
- Population by State/Territory, June 2006 (000s)
- Principal Demographic Indicators
- Principal Demographic Indicators, 1998-2005
- The Australian Healthcare System
- Organisation
- Commonwealth level
- State/Territory & Local Governments
- Healthcare expenditure
- Total Health Expenditure by Source of Funding, 1998/99 - 2004/05 (A$ millions)
- Total Health Expenditure by Type, 2001/02 - 2004/05 (A$ millions)
- Total Health Spending by Type & Source, 2004/05 (A$ millions)
- Health Expenditure by State/Territory, 1998/99 - 2004/05
- Hospitals
- Public/Private Hospitals, 1998/99 - 2004/05
- Private/Public Hospitals by State/Territory, 2004/05
- Public/Private Hospital Beds, 1998/99 - 2004/05
- Public/Private Beds by State/Territory, 2004/05
- Ambulatory Care
- Non-Admitted Patient Occasions of Service, Public Acute Hospitals, 1998/99-2004/05
- Medical personnel
- Medical Practitioners, 1998-2004
- Medical Practitioners by State/Territory, 2001-04
- Medical Specialists, 2002-04
- THE AUSTRALIAN GENERIC PHARMACEUTICAL MARKET
- In Context: the Australian Pharmaceutical Market
- Summary of the Australian Pharmaceutical Market in 2007
- Market Projections, 2007-2012
- Pharmaceutical Expenditure by Source of Funds, 2003/04 - 2005/06 (A$ millions)
- Percentage Change in Pharmaceutical Expenditure, 1999/00 - 2005/06
- PBS prescription data
- PBS Prescriptions, 2001-06 (000s)
- Government Cost of PBS Prescriptions, 2001-06 (A$ millions)
- PBS Prescriptions by ATC Category, 2001-06 (000s)
- Total Cost of PBS Prescriptions by ATC Category, 2001-06 (A$ millions)
- Top 20 PBS Drugs by Volume, 2004-06
- Top 20 PBS Drugs by Cost, 2006 (A$ millions)
- Top 20 Suppliers to the PBS by Value, 2005/06
- Top 20 Suppliers to the PBS by Volume, 2005/06
- Top 20 Suppliers to the PBS by Volume, 2005/06
- Generic Market Size & Projections
- Projected Generic Market, 2006-2012 (A$ millions)
- Projected Generic Market, 2006-2012 (US$ millions)
- Summary Outlook
- Generics in the PBS Market
- PBS Data for leading Generic Manufacturers, 2005/06
- PBS Data for leading Generic Manufacturers, 2005/06 (% of Total)
- Discounting, Mark-ups and Average Price, 2005/06
- Discounting, Mark-ups and Average Price, 2005/06
- Pharmaceutical Regulation
- International harmonisation
- Biosimilars in Australia
- Omnitrope
- EU regulations adopted, 2006
- Mayne Pharma
- Leading Manufacturers & Suppliers
- Summary of Suppliers to the Australian Generic Market, 2007
- Alphapharm Pty Limited
- Financials
- Alphapharm Sales, 2000-06 (million euros)
- Alphapharm PBS Data, 2000-06
- Products
- Alphapharm Drugs Listed on the PBS, January 2008
- US presence
- Alphapharm US FDA ANDA Approvals 2002-07
- Arrow Pharmaceuticals Pty Ltd
- Financials
- Arrow PBS Sales Data, 2005/06
- Products
- Arrow Prescription Drug Products (home developed), 2007
- Arrow Drugs Listed on the PBS, January 2008
- Aspen Australia
- Financials
- Aspen Pharmacare, Australian Sales Results, 2006-07 (million Rand)
- Products
- Aspen Prescription Drugs
- Aspen signs distribution deal with Teva
- Genepharm Pty Ltd
- Financials
- Genepharm Australasia Financial Results, 2006/07 (A$ millions)
- Products
- Genepharm Drugs Listed on the PBS, January 2008
- Supply agreements
- Generic Health Pty Ltd/Bellwether Pharma
- Products
- Bellwether Pharma Drugs Listed on the PBS, January 2008
- GenRx Pty Ltd
- GenRx PBS Sales Data, 2005/06
- Products
- GenRx Drugs Listed on the PBS, January 2008
- Mayne Pharma (Hospira)
- Financials
- Mayne Financial Results, Fiscal 2005-06
- Sales by Category, 2006
- Mayne Pharma PBS Sales, 2003/04 - 2005/06
- Products
- Leading Mayne Pharma Products, August 2006
- Mayne Pharma Drugs Listed on the PBS, January 2008
- US presence
- Mayne Pharma ANDA approvals, 2002-07
- Faulding Pharmaceutical ANDA approvals, 2002-03
- PharmAust
- Ranbaxy Australia Pty Limited
- Products
- Ranbaxy Australia Drugs Listed on the PBS, January 2008
- Sandoz Pty Ltd
- Hexal Australia, PBS Sales 2005/06
- Products
- Sandoz Drugs Listed on the PBS, January 2008
- Sigma Pharmaceuticals (Australia) Pty Ltd
- Products
- Sigma Drugs Listed on the PBS, January 2008
- Orphan Pharmaceuticals
- Winthrop Pharmaceuticals
- Products
- Winthrop Drugs Listed on the PBS, January 2008
- Pricing & reimbursement: PBS
- Selected Generic Medicine Price Comparisons, November 2004 (A$)
- Rise in Co-payment rates, 2005
- Therapeutic Group Premiums
- US Free Trade Agreement
- 12.5% price reductions for new market entrants
- Government announces further PBS reforms, 2006
- Intellectual property
- Data exclusivity
- „Springboarding.
- US Free Trade Agreement, Generic Amendments
- Evergreening?
- Ranbaxy fails to overturn patent on Lipitor
- Pharmaceutical distribution
- Wholesaling
- Top Three Wholesalers, Pharmacy Revenues 2006-07 (A$ millions)
- National Pharmaceutical Services Association
- Australian Pharmaceutical Industries Ltd (API)
- Sigma Pharmaceuticals
- Symbion Health (formerly Mayne Group)
- Retailing
- Community Pharmacies by State/Territory, June 2007
- People per Pharmacy, June 2007
- New wholesaler/pharmacy margin deal agreed
- APPENDIX 1: INTERNATIONAL COMPARISONS
- Generic Pharmaceutical Expenditure
- Generic Pharmaceutical Expenditure, 2007 (US$ billions)
- Generic Pharmaceutical Expenditure per capita, 2007 (US$)
- Generic Pharmaceutical Expenditure as % of Total, 2007
- APPENDIX 2: SOURCES
- Espicom Sources
- Australian Government Sources
- Industry Sources
- APPENDIX 3: EXCHANGE RATES
AbstractThis report provides a complete assessment of the US$1.43 billion Australian generic pharmaceutical market.
Key areas addressed:
- 5-year market forecast to 2012 for value and volume
- The generics market in context of the whole pharmaceutical industry
- Pricing/reimbursement issues
- Extensive prescription data analysis for leading products and companies
- Political, legal and economic assessment
- Insightful review of 12 major domestic and foreign players who lead the generic market
- Extensive background data on the Australian health system
The report answers key questions such as:
- What is the estimated value of the Australian generic market now and in 2012?
- How are price controls affecting generic drugs and how will this change in the future?
- Will Alphapharm continue to dominate in the face of mounting domestic and international competition?
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
